Business
£3 million Innovate UK grant
£3 million Innovate UK grant.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 6474C Oxford Biomedica PLC 23 January 2018 \n\n \n \n \n \n \n \nOxford BioMedica announces £3 million grant awarded by Innovate UK \n \nLondon, UK - 23 January 2018: Oxford BioMedica plc (\"Oxford BioMedica\" or \"the Group\") (LSE:OXB), a leading gene and cell therapy group, has announced it that has been awarded a £3 million grant by the UK's innovation agency, Innovate UK, to support the UK's efforts to produce viral vectors and ensure adequate supply to meet future demand. Reference: corresponding Innovate UK announcement here: https://www.gov.uk/government/news/improved-healthcare-for-all-pioneering-projects-get-funding\nThe aims of this grant are closely aligned with the current government national priorities to make the UK a global hub for manufacturing advanced therapies, which will benefit economic growth and create and retain more highly skilled employment. \nThe grant will be used to support investment in equipment for vector development, vector manufacture, storage and analytical equipment, as well as other items that are key for the operation of vector GMP facilities. In addition, a small part of the grant will be used to support the planning for the transition of GMP suites from the use of adherent to suspension cultures. \nJohn Dawson, Chief Executive Officer of Oxford BioMedica, commented: \"We are delighted that the Innovate UK grant will to keep the UK at the forefront of innovation in industrial viral vector manufacturing. Viral vectors are a crucial component of cell and gene therapies, which offer unprecedented promise for the treatment, long-term management or cure of disease. We are pleased that Oxford BioMedica has been selected to contribute our expertise to ensure continued and uninterrupted supply to meet future viral vector demand.\" \n- Ends -\n \n \n\n\n\n\nFor further information, please contact:\n\n\n \n\n\n\n\n \nOxford BioMedica plc:\nJohn Dawson, Chief Executive Officer\nStuart Paynter, Chief Financial Officer\n \n\n\n \nTel: +44 (0)1865 783 000\n\n\n\n\n \nConsilium Strategic Communications\nMary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton\n \n\n\n \n \nTel: +44 (0)20 3709 5700\n\n\n\n\n \nNotes for editors\n \nAbout Oxford BioMedica\n \nOxford BioMed...